Table 2.
Adverse event* | HIV infected group (n = 154) |
HIV-uninfected group (n = 50) |
p-value | |
---|---|---|---|---|
Immediate - total | 30 (19.48%) | 8 (16%) | 0.78 | |
Local reaction | 24 (15.58%) | 8 (16%) | 0.84 | |
Systemic reactions | 10 (6.49%) | 0 | 0.17 | |
Within 3 days - total | 42 (27.27%) | 3 (6%) | < 0.01 | |
Fever | 5 (3.25%) | 0 | 0.45 | |
Local reaction | 32 (20.78%) | 3 (6%) | 0.07 | |
Systemic reactions | 16 (10.39%) | 0 | 0.07 | |
Within 7 days - total | 15 (9.74%) | 1 (2%) | 0.09 | |
Fever | 2 (1.30%) | 0 | 0.72 | |
Local reaction | 4 (2.60%) | 1 (2%) | 0.84 | |
Systemic reactions | 13 (8.44%) | 0 | 0.09 | |
Total | 66 (42.86%) | 10 (20%) | < 0.01 |
All local reactions were mild (grade 1). No grade ≥ 3 adverse events were reported.